Hypertension Management

Blood Pressure Targets and Treatment

• For patients with blood pressure 130-139/80-89 mmHg, lifestyle and behavioral therapy should be started for a maximum of 3 months, then pharmacological treatment should be added if targets are not achieved, as recommended by the American Diabetes Association 1
• For patients with blood pressure ≥140/90 mmHg, immediate pharmacological treatment plus lifestyle modifications are recommended by the American Diabetes Association 1
• ACE inhibitors or ARBs should be used as the cornerstone of treatment for patients with diabetes, as they delay progression of nephropathy in type 1 diabetes and delay progression to macroalbuminuria in type 2 diabetes, according to the American Diabetes Association 2
• If one class is not tolerated, the other should be substituted, as advised by the American Diabetes Association 2
• The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend ACE inhibitors or ARBs for normotensive people with diabetes and microalbuminuria, with a moderate/weak recommendation 3
• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) or beta-blockers should be considered if target blood pressure is not achieved with ACE inhibitor or ARB monotherapy, as suggested by the American Diabetes Association 2
• Target blood pressure is <130/80 mmHg, according to the American Journal of Kidney Diseases guidelines 3, 4, 5, 6, 7
• If target blood pressure is not achieved with ACE inhibitor or ARB monotherapy, adding a diuretic as second-line therapy or considering non-dihydropyridine calcium channel blockers or beta-blockers is recommended 4, 5, 6, 7
• Combination therapy with ACE inhibitor, ARB, and direct renin inhibitor should be avoided due to increased risk of hyperkalemia and acute kidney injury, as advised by the American College of Physicians 8

Lifestyle Modifications

• Optimize glycemic control with target HbA1c <7.0%, as recommended by the American Diabetes Association 2
• Protein intake should be 0.8 g/kg body weight/day, with consideration for further restriction to 0.6 g/kg/day if GFR begins to fall, according to the American Diabetes Association and the American Heart Association 2
• Dietary management should be designed by a registered dietitian familiar with all components of diabetes management, as recommended by the American Diabetes Association 2
• Sodium restriction to <2 g of sodium per day is advised by the American College of Cardiology to reduce blood pressure and cardiovascular risk 8
• Regular exercise, at least 150 minutes per week of moderate-intensity exercise, is recommended by the American Heart Association to improve cardiovascular health and reduce kidney disease risk 8
• Weight normalization if overweight or obese is recommended by the National Kidney Foundation and the American Diabetes Association 2, 4, 9, 4, 10

Monitoring and Follow-up

• Regular monitoring of serum creatinine, potassium, and urine microalbumin ratio is essential to assess treatment response and adjust therapy as needed, according to the American Diabetes Association 11, 12, 13, 14, 4, 2, 15
• Annual assessment of renal function regardless of albuminuria status is recommended by the American College of Physicians to detect early signs of kidney disease progression 11
• Monitoring of serum creatinine and potassium within 1-2 weeks of starting therapy is recommended, with continuation of treatment even if serum creatinine increases up to 30% from baseline without hyperkalemia, as advised by the American Diabetes Association 16, 17, 13, 10
• Retesting of microalbuminuria within 6 months to assess treatment response is recommended, as advised by the American Diabetes Association 12, 13, 14, 4, 2, 15
• Consider referral to a nephrologist when GFR has fallen to <60 ml/min/1.73 m² or difficulties occur in managing hypertension or hyperkalemia, as recommended by the American College of Physicians 2, 5, 17, 5

Cardiovascular Risk Reduction

• Optimizing glycemic control with a target HbA1c <7.0% reduces the risk of kidney disease progression and cardiovascular events, as recommended by the American Diabetes Association 2, 4, 17, 13, 3, 5, 6, 7
• Initiation of statin therapy reduces cardiovascular risk, as recommended by the American College of Cardiology 2
• Addressing all modifiable cardiovascular risk factors, including smoking cessation, dyslipidemia management, and weight management, is essential to reduce cardiovascular risk, according to the American Heart Association 2, 17, 5, 7
• Microalbuminuria indicates increased cardiovascular risk beyond kidney disease, and addressing all modifiable cardiovascular risk factors is essential, as recommended by the American Diabetes Association and the American College of Cardiology 17, 5, 7, 2

Evidence from Clinical Trials

• The RENAAL study demonstrated that losartan reduced the risk of doubling serum creatinine by 25% and end-stage renal disease by 29% in type 2 diabetics with nephropathy, as reported in the American Journal of Kidney Diseases 18
• The benefits of ACE inhibitor or ARB therapy in reducing progression of kidney disease outweigh the risks when appropriate monitoring is implemented, as suggested by the American Journal of Kidney Diseases 3